DO-BO

How Can Europe Move from Innovation Paradox to Powerhouse,  Cuno Moser?

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer engages with Swiss healthcare strategist Cuno Moser to explore Europe’s “innovation paradox” in healthcare. Despite its strengths in research, data quality, and clinical expertise, Europe struggles to transform pilot projects into scalable, reimbursable solutions. With over 27 fragmented reimbursement systems in the EU and in Switzerland, significant barriers impede progress in digital health, medtech, and AI-driven care. Beyond funding, challenges such as misaligned incentives, insufficient execution infrastructure, and flawed system design keep innovation stuck in “pilot purgatory.”

Looking ahead, while Europe may not lead in speed, it has the opportunity to excel in quality and trust. This could allow European health platforms to establish a competitive edge. If you’re involved in digital health, medtech, AI, or market access and find your solution stalled between a promising pilot and real-world scalability, this episode is a must-listen.

https://www.linkedin.com/feed/update/urn:li:activity:7437804838232453120/

Related

AI is reshaping health economics and outcomes research (HEOR) – but where does it truly belong? In this MAP episode, Dr. Stefan Walzer talks with Haidong Feng, Associate Principal Scientist at Merck, about “human in the loop” versus “AI in the loop” and why the two complement rather than contradict each other. Haidong explains why […]

When the US benchmarks drug prices against other countries, the whole world feels it. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Brittany La Couture of Applied Policy, a health policy attorney with eight years at the Centers for Medicare & Medicaid Services, to unpack the US […]

In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Rainer Westermann, Chairman of the Life Sciences Acceleration Alliance (LSAA), to ask whether Europe can remain a globally competitive home for life sciences innovation — and what has to change for new therapies to reach patients. Bringing an investor’s […]